Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;11(2):e004278.
doi: 10.1161/CIRCHEARTFAILURE.117.004278.

MicroRNAs Associated With Reverse Left Ventricular Remodeling in Humans Identify Pathways of Heart Failure Progression

Affiliations

MicroRNAs Associated With Reverse Left Ventricular Remodeling in Humans Identify Pathways of Heart Failure Progression

Ravi Shah et al. Circ Heart Fail. 2018 Feb.

Abstract

Background: Plasma extracellular RNAs have recently garnered interest as biomarkers in heart failure (HF). Most studies in HF focus on single extracellular RNAs related to phenotypes and outcomes, and few describe their functional roles. We hypothesized that clusters of plasma microRNAs (miRNAs) associated with left ventricular (LV) remodeling in human HF would identify novel subsets of genes involved in HF in animal models.

Methods and results: We prospectively measured circulating miRNAs in 64 patients with systolic HF (mean age, 64.8 years; 91% men; median LV ejection fraction, 26%) with serial echocardiography (10 months apart) during medical therapy. We defined LV reverse remodeling as a 15% reduction in LV end-systolic volume index. Using principal components analysis, we identified a component associated with LV reverse remodeling (odds ratio=3.99; P=0.01) that provided risk discrimination for LV reverse remodeling superior to a clinical model (C statistic, 0.58 for a clinical model versus 0.71 for RNA-based model). Using network bioinformatics, we uncovered genes not previously widely described in HF regulated simultaneously by >2 miRNAs. We observed increased myocardial expression of these miRNAs during HF development in animals, with downregulation of target gene expression, suggesting coordinate miRNA-mRNA regulation. Target mRNAs were involved in autophagy, metabolism, and inflammation.

Conclusions: Plasma miRNAs associated with LV reverse remodeling in humans are dysregulated in animal HF and target clusters of genes involved in mechanisms implicated in HF. A translational approach integrating human HF, bioinformatics, and model systems may uncover novel pathways involved in HF.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00351390.

Keywords: RNA, messenger; downregulation; heart failure; microRNAs; myocardium.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr. Murthy discloses minor holdings in General Electric. Dr. Tackett is an employee of Abcam (the owners of the FirePlex platform used in this study). Dr. Shah is a consultant for MyoKardia, Inc., Best Doctors, Inc., and Amgen, Inc., none of which had a role in this study. Dr. Das is a founding member of Dyrnamix, which had no role in this study.

Figures

Figure 1
Figure 1
Principal components analysis of selected miRNAs. Loadings are also given in Supplemental Table 2. Black outlines on the loadings signify those miRNAs loaded at greater than or equal to 60.
Figure 2
Figure 2
ROC curve for logistic regression models for beneficial remodeling as a function of principal component 2 (with cross-validation).
Figure 3
Figure 3
Connectome between miRNAs in Principal Component 2 and predicted and experimental gene targets. This figure represents the subnetwork of proteins targeted by 2 or more miRNAs. Nodes targeted by 3 miRNAs are in green, and interactions weighted based on the strength of evidence, interactions with strong evidence are thicker.
Figure 4
Figure 4
miRNAs in circulation in humans with LVRR are dynamically expressed in mice during HF development. (A) Myocardial expression of miRNAs in a mouse model of pressure overload hypertrophy (TAC). This experiment represents 8 shams, 4 LVH, and 9 HF mice. Fold change versus sham controls is presented (details in text). Error bars represent standard error in fold change. The asterisks indicate significance (at a Bonferroni type 1 error 0.05/3 comparisons: sham vs. LVH, sham vs. HF, HF vs. LVH) between sham and LVH or sham and HF. Of note, between LVH and HF stage, only miR-208a exhibited a significant difference. (B) Myocardial expression of mRNAs targeted by multiple miRNAs in Panel (A) in TAC. This experiment represents 8 shams, 4 LVH, and 9 HF mice. Fold change versus sham controls is presented (details in text). Error bars represent standard error in fold change. The asterisks indicate significance (at a Bonferroni type 1 error 0.05/3 comparisons: sham vs. LVH, sham vs. HF, HF vs. LVH) between sham and LVH or sham and HF. Of note, there were no significant differences in expression between LVH and HF stage for any mRNAs.
Figure 4
Figure 4
miRNAs in circulation in humans with LVRR are dynamically expressed in mice during HF development. (A) Myocardial expression of miRNAs in a mouse model of pressure overload hypertrophy (TAC). This experiment represents 8 shams, 4 LVH, and 9 HF mice. Fold change versus sham controls is presented (details in text). Error bars represent standard error in fold change. The asterisks indicate significance (at a Bonferroni type 1 error 0.05/3 comparisons: sham vs. LVH, sham vs. HF, HF vs. LVH) between sham and LVH or sham and HF. Of note, between LVH and HF stage, only miR-208a exhibited a significant difference. (B) Myocardial expression of mRNAs targeted by multiple miRNAs in Panel (A) in TAC. This experiment represents 8 shams, 4 LVH, and 9 HF mice. Fold change versus sham controls is presented (details in text). Error bars represent standard error in fold change. The asterisks indicate significance (at a Bonferroni type 1 error 0.05/3 comparisons: sham vs. LVH, sham vs. HF, HF vs. LVH) between sham and LVH or sham and HF. Of note, there were no significant differences in expression between LVH and HF stage for any mRNAs.
Figure 5
Figure 5
Rat neonatal cardiomyocyte expression of miRNAs during phenylephrine treatment. This experiment represents 6 control and 8 phenylephrine treated cell cultures. Fold change versus control is presented (details in text). Error bars represent standard error in fold change. The asterisks indicate significant comparisons (P<0.05) between control and phenylephrine.
Figure 6
Figure 6
Rat neonatal cardiomyocyte expression of mRNAs targeted by miR-423 or miR-212 transfection. This experiment represents 8 control and 8 each of miR transfections in cell culture. Fold change versus control is presented (details in text). Error bars represent standard error in fold change. The asterisks indicate significance (P<0.05) between miR-212 or miR-423 transfection and control. The genes targeted by miR-423 and/or miR-212 are denoted below the x axis.

Comment in

Similar articles

Cited by

References

    1. Boettger T, Braun T. A new level of complexity: the role of microRNAs in cardiovascular development. Circ Res. 2012;110:1000–13. - PubMed
    1. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res. 2012;110:508–22. - PubMed
    1. Zhu H, Fan GC. Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res. 2012;94:284–92. - PMC - PubMed
    1. Leptidis S, El Azzouzi H, Lok SI, de Weger R, Olieslagers S, Kisters N, Silva GJ, Heymans S, Cuppen E, Berezikov E, De Windt LJ, da Costa Martins P. A deep sequencing approach to uncover the miRNOME in the human heart. PLoS One. 2013;8:e57800. - PMC - PubMed
    1. Naga Prasad SV, Duan ZH, Gupta MK, Surampudi VS, Volinia S, Calin GA, Liu CG, Kotwal A, Moravec CS, Starling RC, Perez DM, Sen S, Wu Q, Plow EF, Croce CM, Karnik S. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem. 2009;284:27487–99. - PMC - PubMed

Publication types

Associated data